Get startedLog in
    Picture of Genmab A/S logo

    GMAB — Genmab A/S News Story

    0.000.00%
    dk flag iconLast trade - 00:00
    HealthcareAdventurousLarge CapFalling Star
    All News

    Brief: Genmab Announces Data From Multiple Clinical Trials

    Picture of Genmab A/S logoGenmab A/S
    08/12/2025 07:57
    Dec 8 (Reuters) - Genmab A/S GMAB.CO:

SAID ON FRIDAY ANNOUNCES DATA FROM MULTIPLE CLINICAL TRIALS

NEW TWO- AND THREE-YEAR EPCORE® NHL-2 FOLLOW-UP DATA EVALUATING EPCORITAMAB IN COMBINATION WITH STANDARD OF CARE REGIMENS DEMONSTRATE REMISSION IN PATIENTS WITH DLBCL AND FL

LATEST EPCORE DLBCL-3 TRIAL RESULTS SHOW ENCOURAGING OVERALL RESPONSE AND COMPLETE RESPONSE RATES FOR EPCORITAMAB MONOTHERAPY IN NEWLY-DIAGNOSED, ELDERLY PATIENTS WITH DLBCL

DATA REINFORCE THE POTENTIAL UTILITY OF EPCORITAMAB IN EARLIER LINES OF THERAPY WITH A FIXED TREATMENT DURATION

 Source text for Workspace: nBw9TTV0Ta
 Further company coverage: GMAB.CO

 (Gdansk Newsroom)

 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))

    Recent news on Genmab A/S

    See all news